Studies Done In The Past Have Also Shown The Importance Of Gene Therapy In Treating Cancers

This is not the first study which has shown the efficacy of gene therapy in the treatment of cancer. In fact, in a study published in the New England Journal of Medicine in 2011, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine were able to achieve year-long remission in patients suffering from advanced chronic lymphocytic leukemia (CLL) after they were treated with genetically engineered versions of their own T cells.

There are almost 15,000 new cases of CLL diagnosed in America every year and of these 4,400 patients succumb to the disease annually.

The three patients treated in this study had no option other than undergoing bone marrow transplant. Even then, the chances of cure are just 50%. The researchers obtained the T cells of these patients. These cells were then reprogrammed with the help of lentivirus vector. The vector encodes the T cells to release a chimeric antigen receptor (CAR) on its surface which binds with the CD19 protein present on the surface of B cells. The CAR antigen also produces cytokines which triggers the multiplication of more and more T cells until all the tumor cells are destroyed.

As the tumor cells are destroyed very rapidly, patients may complain of violent reactions for a short duration of time. These include flu like symptoms like fever, chills and nausea. In scientific parlance, this is called as tumor lysis syndrome, i.e. the time when a large number of tumor cells are destroyed at one go. However, these symptoms subside within four weeks and then, there are no traces left of the tumor cells.

The researchers plan to use gene therapy in other CD19 positive cancers like non-Hodgkin's lymphoma and acute lymphocytic leukemia. Buoyed by the results obtained in the study, the researchers have also created specially engineered T cells which can bind with a protein called mesothelin. This protein is found in mesothelioma cancer cells, ovarian cancer cells and pancreatic cancer cells. If the scientists are able to achieve similar results, it would amount to a revolution in the treatment of cancers.

Although the results of these studies have been very encouraging, the downside is that the normal B cells are also killed in the process. Therefore the patients are more prone to develop infections subsequently. The scientists have been trying to evolve means to avoid this collateral damage. In a new study, published in the Proceedings of the National Academy of Sciences in March 2013, researchers have been able to successfully target only the CLL cells while leaving the normal B cells intact.

Apart from CD19, CLL cells also express another glycoprotein called as CD44. The researchers have identified a monoclonal antibody called RG7356 that specifically targets CD44 and destroys the CLL cells without causing any damage to the normal B cells. Moreover, the CLL cells which express a protein called as ZAP-70 and have been acted upon by the monoclonal antibody, undergo programmed cell death.

In yet another study published in the April issue of the New England Journal of Medicine, researchers led by Stephan A. Grupp, Director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, have described how two children with ALL have attained complete remission from their disease after undergoing gene therapy. Here again, the researchers genetically modified the T cells to target the cancer cells. But in this study, one of the children suffered a relapse due to emergence of cancer cells that did not possess the target cell receptor protein. The researchers are now trying to identify other surface proteins present on the cancer cells.

These studies have suddenly generated considerable interest in gene therapy for treating cancers. There is considerable ongoing research in this field and future of cancer treatment definitely looks bright.